Compare Smith & Nephew plc (SNN) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Williams-Sonoma, Inc. — how do they compare? Smith & Nephew plc trades at $30.05 (market cap $12.54B), while Williams-Sonoma, Inc. trades at $250.52 (market cap $29.51B). The key difference: Williams-Sonoma, Inc. is far larger — about 2.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| SNN | WSM | |
|---|---|---|
Market Cap | $12.54B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $38.70 | $251.81 |
52-Week Low | $28.73 | $168.64 |
Enterprise Value | $15.57B | $30.35B |
Dividend Yield | 2.65% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Williams-Sonoma (WSM) trades at $245.16, down 2.26% today, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 13.81% net income margin and 54.01% ROE, supported by recent earnings beats. Recent news highlights investor interest and a CEO stock sale, while cash flow trends show variability, with 2025 net cash flow at -$49 million.
Outlook remains positive with consistent earnings performance and a 'Moderate Buy' analyst consensus, though risks include consumer discretionary sector volatility and competitive pressures. The stock trades above the consensus price target of $231.10, suggesting limited near-term upside based on current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
